SLC2A1 and colonic neoplasm: The use of glucose transporter 1 (GLUT1) inhibitor IV, WZB117, caused a decreased glucose uptake into HT29 colon cancer cells, whereas a higher glucose influx was detected during stimulation with PDGF (Figure 8A).